|
|
Article: Avanir Buys Alamo, Gains CNS Product, Sales Force.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
As it prepares for an FDA approval and launch of its second product, Neurodex, Avanir Pharmaceuticals Inc. agreed to buy Alamo Pharmaceuticals LLC for $29 million in up-front costs, as well as a potential $40 million in sales milestone payments.
Alamo is a private specialty pharmaceutical firm based in Los Angeles, but with a facility in Parsippany, N.J., the headquarters of its commercialization efforts for its marketed product FazaClo (clozapine). A team of about 50 sales representatives currently markets FazaClo, an orally disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to ...